Total
0
Shares
Advanced Human Imaging (ASX:AHI) - CEO, Vlado Bosanac
CEO, Vlado Bosanac
Source: Advanced Human Imaging
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Advanced Human Imaging (AHI) teams up with Singapore-based Bizbaz to integrate technologies
  • Under the agreement, AHI will integrate its CompleteScan technology into the Bizbaz application, which is expected to be released in December
  • Bizbaz offers financial and health intelligence solutions to financial, wellness and insurance institutions, fintech and eCommerce companies in Asia
  • On the market this afternoon, AHI is up 2.46 per cent and is trading at $1.25 per share

Advanced Human Imaging (AHI) has teamed up with Singapore-based Bizbaz to integrate technologies.

Under the agreement, AHI will integrate its CompleteScan technology into the Bizbaz application.

Bizbaz offers financial and health intelligence solutions to financial, wellness and insurance institutions, fintech and eCommerce companies in Asia.

The business provides these solutions through gamification and consumer ownership.

Gamification involves adding game mechanics into non-game environments such as websites and online communities. The goal of this technique is to engage with consumers, employees and partners to collaborate, share and interact.

“Engagement through gamification is great a way to bring health and wellness to the Bizbaz communities. The gamification of a health score with rewards has been well-received globally with companies such as Vitality and Bearn, so I am eager to see how Bizbaz approach this in their own unique way,” AHI CEO Vlado Bosanac said.

“Bizbaz identified the consumer engagement capabilities of the CompleteScan platform and its ability to deliver a diverse and valuable data set to both its health and insurance partners as well as the partners consumers.”

Bizbaz plans on releasing the app in December and aims to reach 100,000 active users in the first 12 months.

“We have been looking for a cutting edge Healthtech provider for a while, and having considered a few came across AHT’s technology, which we found amazing,” Bizbaz CEO Hayk Hakobyan said.

“Similar to us, they have been building their tech on latest research and the health and wellness related insights they provide just from CompleteScan, which is very much what we have been wanting to incorporate in our risk profiling for financial
institutions, especially the insurance sector.”

On the market this afternoon, AHI is up 2.46 per cent and is trading at $1.25 per share at 1:09 pm AEST.

AHI by the numbers
More From The Market Herald
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.
Dimerix (ASX:DXB) - Managing Director & CEO, Dr Nina Webster

" Dimerix (ASX:DXB) receives approvals to start Phase 3 kidney damage trial

Dimerix (DXB) has been granted Australian ethics and regulatory approval for its Phase 3 clinical trial in FSGS kidney patients.